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Abstract: The 8-hydroxyquinoline pharmacophore scaffold has been shown to possess a range of 
activities as metal chelation, enzyme inhibition, cytotoxicity, and cytoprotection. Based on our 
previous findings we set out to optimize the scaffold for cytoprotective activity for its potential 
application in central nervous system related diseases. A 48-membered Betti-library was 
constructed by the utilization of formic acid mediated industrial-compatible coupling with sets of 
aromatic primary amines such as anilines, oxazoles, pyridines, and pyrimidines, with 
(hetero)aromatic aldehydes and 8-hydroxiquinoline derivatives. After column chromatography and 
re-crystallization, the corresponding analogues were obtained in yields of 13–90%. The synthesized 
analogs were optimized with the utilization of a cytoprotection assay with chemically induced 
oxidative stress, and the most active compounds were further tested in orthogonal assays, a real 
time cell viability method, a fluorescence-activated cell sorting (FACS)-based assay measuring 
mitochondrial membrane potential changes, and gene expression analysis. The best candidates 
showed potent, nanomolar activity in all test systems and support the need for future studies in 
animal models of central nervous system (CNS) disorders. 
Keywords: 8-hydroxyquinoline; 8-HQ; Mannich-reaction; Betti-reaction; multicomponent reaction; 
cytoprotection; phenotypic screening; neurodegeneration; multitarget directed ligand; 
mitochondrial membrane potential; HIF1A 
 
1. Introduction 
In the last two decades, the 8-hydroxyquinoline (8-HQ) structure have emerged as a promising 
pharmacophore scaffold for medicinal chemists, due to a coded biological and synthetic potential 
owing to the active sites in the molecule on C-2, C-5, and C-7 carbons [1]. The presence of hydroxyl 
substituent on the C-8 carbon creates an ortho (C-7) and/or para (C-5) direction, providing active 
positions for electrophilic aromatic substitutions on C-5 (para) and for the accomplishment of aza 
Fiedel-Crafts-type reactions, including Mannich- or Betti-three components reactions (Mannich-3CR 
and Betti-3CR) predominantly on the C-7 (ortho) position. Higher molecular diversity and the 
formation of a new chiral carbon centre could be achieved by the use of Betti-3CR: treatment of 
several (aromatic) aldehydes with primary amines then 8-HQ, 5-nitro-, or 5-chloro-8-HQ. The 
application of Mannich-3CR of simple formaldehyde and secondary amines as an iminium source for 
addition, is highlighted for biological utilization [2,3]. Based on previously published biological 
studies, the structurally modified 8-HQs exert two main activities depending on the C-7 function and 
substitution pattern of the mother compound, 8-HQ. These compounds are either cytotoxic or active 
in cytoprotection assays. These studies describe a variety of 7-aminomethylated 8-HQ, 5-chloro-8-
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HQ and 5-nitro-8-HQ (nitroxoline) as products of different multicomponent reaction (MCR) 
techniques in different hit-to-lead optimizations. 
1.1. Cytotoxicity 
The most promising cytotoxic 8-HQ analogues were depicted in Figure 1. They act through 
different mechanisms, namely the inhibition of Cathepsin B, KDM4 histone demethylases, 2-
oxyglutarate oxygenase subtypes, and lipoxygenase (LOX)-enzymes [4–10]. Among the enzyme 
inhibitors, eutomer (−)-Betti products were presented with excellent, selective 12-LOX inhibition; 
moreover, these products were tested successfully in in vivo experiments. Additionally, INP1750 has 
a Gram-negative pathogen selective antibacterial effect [11]. Interestingly, if an N-sulfonated 
piperazine-1-yl unit was introduced in the C-7 position, the Mannich derivatives exerted an 
improved growth-inhibitory effect that was 26-fold more potent than that of 5-chloro-8-HQ against 
HeLa cells [12,13]. 
 
Figure 1. Cytotoxic 8-hydroxyquinoline (8-HQ) analogues. 
It is notable that the inhibitor activities were explained by an improved metal chelating ability 
compared with the parent compound 8-HQ, due to optimal copper and zinc(II)-binding in vivo 
[1,6,11,12,14]. 
1.2. Cytoprotection 
In contrast with mentioned enzyme inhibition and antitumor activities, a number of 8-HQ 
derivatives possessed cytoprotective activities.  
As a suitable example, clioquinol (CQ, 5-Chloro-7-iodoquinolin-8-ol) has a selective, but low 
binding ability for Zn2+/Cu2+-ions, and it exerts potency against several neurodegenerative disorders 
(Huntington, Alzheimer’s, and Parkinson diseases) but its toxicity in long-term administration 
restricts its use in the clinic [15–18]. Structural modifications on the parent compound CQ have 
afforded second generation Zn2+/Cu2+ ionophores such as the PBT family (C-2 substituted 5,7-
dichloro-8-HQ e.g. PBT2 (5,7-Dichloro-2-[(dimethylamino)methyl]quinolin-8-ol)) or their related 
structures, which have increased blood brain barrier permeability, more solubility, and less toxicity. 
In addition, PBT2 progressed to Phase IIa clinical trials as an anti-Alzheimer agent [19–22]. The 
multifunctional characteristics of these 8-HQ analogs provide the basis for the emerging use of 
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multitarget-directed ligand (MTDL) treatment of neurogenerative diseases possessing a 
multifactorial nature e.g. Alzheimer’s disease. 
An interesting medicinal chemistry concept is based on the formation of 8-HQ-hybrids (Figure 
2). Known pharmacophores e.g. propargil or N-benzyl piperidine/piperazine moieties were 
substituted in C-2, C-5, or C-7 positions of 8-HQ creating analogues with an improved cytoprotective 
action. In fact, a series of 2- and 5-functionalized-8-hydroxyquinoline hybrid structures, HLA-20, 
M30, VK28, and MTDLs act as potent anti-neurodegenerative agents, exert significant inhibition of 
β-amyloid aggregation in vitro, decrease metal-driven oxidative damage and β-amyloid-mediated 
neurotoxicity. In addition, considerable cholinesterase inhibition, ROS scavenging, and an anti-
aggregating effect on Aβ42 has been assessed [23–36]. These compounds incorporate known 
pharmacophore synthones from rasagiline (HLA20), donepezil (MTDL3 and MTDL4), or from 
rivastigmine (VK28). As a result of original framework combinations, a subclass of C-7-hybrides were 
also prepared by fusing N-benzyl piperazines/piperidines to 8-HQ, utilizing optimized Mannich-3CR 
conditions [37]. 
 
Figure 2. Cytoprotective 8-HQ derivatives. 
Interestingly, C-2 hydrazones, thiosemicarbazones, and semicarbazones modulate the Cu-Aβ 
peptide interactions as well. 8-HQ-2-hydrazones (INHHQ) were proved to be well-tolerated, stable 
derivatives which are able to cross the blood-brain barrier (BBB) and act as anti-Parkinson agents 
[38,39]. 
Phenotypic screening for functionally distinct 8-HQ derivatives on a yeast TAR DNA-binding 
protein 43 (TDP-43) toxicity model indicated a considerable reverse action for the expression of the 
TDP-43 protein in the case of compound HQ415 (Figure 2) [40]. Moreover, CQ can modulate 
amyloidogenic proteins/peptides and consequently it can be effective in Alzheimer’s disease, but its 
structural modifications towards Betti-bases (e.g., HQ415) resulted in significantly higher potency in 
neuronal proteotoxicity models, presumably due to having an effect on the process of oxidative stress 
and misregulation of iron metabolism besides enzyme inhibition [41]. 
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Novel cytoprotective screening assays revealed Betti-bases as being a new subclass of potent 
cytoprotective agents; nevertheless, a few number of analogues had been analyzed up to now (Figure 
2). During the utilization of a cell-microelectronic sensing technique (RT-CES), a small-membered Q-
library, composed of seven commercially available 8-HQ analogues, was tested for cytoprotective 
activity in real-time to identify possible hit compound(s) against cardiac diseases. Notably, 
compound Q3 implicated 8-HQ, benzocain, and benzaldehyde motifs, emerging as a suitable 
candidate for a hit-to-lead optimization [42]. Systematic preparative efforts led to the analogue Q50, 
which was proven to be highly potent in improving cardiac functional recovery of 
ischemic/reperfused myocardium in rats [43]. 
The current work describes the optimization of the 8-HQ Betti products for cytoprotective 
activity in glioblastoma cells as a model for neuroprotection, as well as for possible application in 
CNS-related disorders. 
2. Results and Discussion 
Scheme 1 depicts the general synthetic procedures for the synthesis of products 1–48. For a 
comprehensive biological evaluation, several primary aromatic amines, aromatic aldehydes and 8-
hydroxyquinolines were subjected to the Betti-3CR. Notably, the achievement of a suitable optimal 
condition and access to a large number of Betti-compound libraries is a great challenge, owing to the 
fundamental Betti-conditions that proceed with very poor yields, and its improvement is strongly 
dependent on the applied amine and/or aldehyde components. 
 
Scheme 1. General protocol for the synthesis of compounds 1–48. 
For a rapid synthetic method, a known industrial application was chosen to access a diverse 
chemical library. For the assemblies, 1 v/v % formic acid was exploited as Brönsted-acid mediator in 
acetonitrile at 75 °C. We focused on the preparation of Betti compounds with high purities regardless 
of the yields and optimal conditions. 
At first, an optionally selected 15-membered basic library was prepared and assessed in a 
cytoprotection assay to reveal the possible next step for a synthetic strategy. Following a medicinal 
chemistry protocol, the 8-HQ was conducted by means of simple amine inputs such as aniline, 2-
aminopyridine, 2-aminopyrimidine, and 3-aminoisoxazol in combination with unsubstituted 
benzaldehyde and 2-pyridinecarbaldehyde as a N-containing substrate. In addition, several 
structural modifications were accomplished to prepare some substituted variants by altering either 
the amine or aldehyde components. In accordance with that, 10 other examples were synthesized 
using substituted benzaldehydes, containing electron withdrawing (CF3, F, and NO2) or electron 
donating (O-alkyl) group in the para position, in combination with e.g., benzocain, p-benzoic acid 
(PABA), 5-alkyl (methyl or tert-butyl)-substituted isoxazoles, or 6-picoline. 
For pyrimidine based analogues, only two derivatives were presented, consisting of 
unsubstituted pyrimidine units with phenyl (from benzaldehyde) or 4-nitrophenyl (from p-
nitrobenzaldehyde) moieties.  
In all cases, the formic acid-mediated Betti-transformations were accomplished to furnish the 
pure desired products 1–15 in yields of 12–40% (Scheme 2). 
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Scheme 2. The tested basic chemical library with half maximal inhibitory concentration (IC50) values 
in a cytoprotection assay. Each analog was prepared with the combination of the shown aldehydes, 
substituted amines, and 8-HQ. 
2.1. Primary Assay 
We have utilized a simple and inexpensive method to screen our 8-HQ analogs for 
cytoprotective activity. U251 MG glioblastoma cells were exposed to hydrogen peroxide to induce 
oxidative stress, and the effects of co-treatment with the synthesized compounds were investigated 
after a 24 h incubation by a fluorimetric endpoint assay. Cytoprotective compounds could be 
identified by resulting in more live cells after a peroxide challenge. 
2.2. Structure Activity Relationship 
Gratifyingly, the first assessment delineated a preliminary structure-activity relation (SAR), and 
demonstrated a high cytoprotective potential, due to the Betti-structure. In fact, we observed sub-
micromolar activities in most cases, except for compounds 5 and 7 (1.05 µM and 2.03 µM). 
Consequently, application of PABA and non-substituted isoxazoles as an amine source is not 
suggested for further application. Despite that, presence of an alkyl function on C-5 position for the 
isoxazole ring significantly increases the efficiencies, as shown in case of compounds 8–10 (IC50 (8–10) = 
0.15, 0.49, and 0.25 µM). Interestingly, substitutions of the amine or aldehyde are capable of 
enhancing the cytoprotective activity as demonstrated by the changing IC50 values in the range from 
2.03 µM towards 0.11 µM. Based on these preliminary results, we assumed that it was possible to 
increase the scaffold’s potential; however, the perfect substitution pattern could not be drawn due to 
similar sub-micromolar activities for differently oriented substitution patterns in starting substrates.  
Accordingly, further synthetic efforts could not be limited to one mainstream biological 
optimization process, with a focus on the variation of either the amine or the aldehyde reagents; 
rather, our strategy is based on the construction of a chemical library involving three subclasses 
(substituted anilines (Subclass 1), 2-aminopicolines (Subclass 2) and 2-aminopyrimidines (Subclass 
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3)) to demonstrate structure-activity relations and to give a chance to select lead-like compounds for 
the final assessment. 
Coupling of benzocaine (presence of para-COOEt group) instead of aniline with 4-CF3–
benzaldehyde and 8-HQ slightly attenuated the biological activity of derivative 16 from 0.15 µM (for 
2) to 0.19 µM (Table 1). On the other hand, slightly better results were obtained by the substitution of 
R′′ = 4-F–C6H4 (analogues 4; IC50 = 0.11 µM) with a 2-pyridyl group (analogues 17; IC50 = 0.12 µM). 
Interestingly, the application of benzocaine for the construction of a 2-pyridyl-containing analogue 
17 improved the cytoprotection potential significantly (compound 3 with IC50 = 0.40 µM in 
comparison with 17, IC50 = 0.12 µM). Moreover, replacement of the carbetoxy group with a NO2 or 
CF3 moiety resulted in synthesized compounds with excellent efficiency in cytoprotection, with 0.09 
µM (R′ = 4-CF3–C6H4 and R′′ = 2-pyridyl; compound 18) and 0.12 µM (R′ = 4-NO2–C6H4 and R′′ = 2-
pyridyl; compound 19) IC50 values.  
From Subclass 1, three superior compounds 17 and 18 besides analogue 4 were selected as lead-
like compounds. 
Table 1. Betti-three components reactions (3CR) results, use of several anilines and aldehydes 
(Subclass 1). 
 
Compounds Amine (R′) Aldehyde (R′′) Yield (%) a IC50 (µM) SD 
16 
  
30 0.195 0.143 
17 
  
60 0.122 0.029 
18 
  
33 0.096 0.033 
19 
  
14 0.125 0.024 
a after column chromatography and crystallization. 
For the picoline family, basic compounds 6, 11, 12, and 13 highlighted the suitable reagent 
combination, such as para-substituted aldehydes, regardless of the electronic nature of the 
substituents and/or 6-picoline. Moreover, incorporation of the R′′ = 2-pyridyl unit in compound 13 
(IC50 = 0.687 µM) resulted in a weak cytoprotective potential in comparison with benzaldehyde-based 
analogues 11 (R′′ = 4-F–C6H4; IC50 = 0.158 µM) and 12 (R′′ = 4OCH(CH3)2–C6H4; IC50 = 0.289 µM). 
Although, both of electron withdrawing group (EWG)- or electron donating group (EDG)-substituted 
analogues possess higher activity than the unsubstituted such as compound 6 or the 2-pyridylform 
13, 11 with para-fluoro moiety on the R′′ position demonstrated better efficiency. 
In a pyridine-based optimization a tendency could be outlined by introducing a para–
trifluoromethyl or para–nitrophenyl group on the R′′ function, causing a remarkable positive effect. 
For a first improvement, the tested analogues 20 and 21 exerted excellent activity with IC50 = 0.087 
µM and 0.086 µM values. Notably, their representative C-2 methylated variant 23 had diminished 
cytoprotection levels, thus the 8-hydroxyquinaldine proved to be an unsuitable component for the 
development process. Afterwards, we considered the in-vivo or in-use feasibilities of nitro and 
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trifluoromethylated derivatives in future studies. For possible toxicity issues therefore, we decided 
that the trifluoromethylated structure 20 would be the favored scaffold for further modification, and 
that the development of nitro derivatives was terminated. In the next steps, the positions of the 
trifluoromethyl and the picolines methyl group were varied, resulting in a slightly decreased IC50 
range: 0.156–0.166 µM were observed for cases 25–27. Interestingly, application of di-substituted 
aldehydes involving trifluoromethyl and/or fluoro substituents in 2,4-; 3,4-, and 3,5-positions resulted 
in molecules 28–32, which displayed a decreased biological activity with an IC50 = 0.204 µM at best 
(Table 2). Based on these observations, 20 and 21 picoline derivatives were selected for the final study. 
Table 2. Functionalization with several picolines (Subclass 2). 
 
Compounds Amine (R′) Aldehyde (R′′) R Yield (%) a IC50 (µM) SD 
20 
  
H 33 0.087 0.028 
21 
  
H 51 0.086 0.046 
22 
  
Me 23 0.562 0.136 
23 
  
Me 71 0.824 0.390 
24 
  
H 34 0.135 0.073 
25 
  
H 62 0.156 0.052 
26 
  
H 18 0.166 0.040 
27 
  
H 15 0.156 0.078 
28 
 
 
H 35 0.206 0.168 
29 
 
 
H 43 0.379 0.217 
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30 
  
H 90 0.246 0.171 
31 
 
 
H 22 0.460 0.199 
32 
  
H 53 0.204 0.111 
a after column chromatography and crystallization. 
Although the preliminary test defined high potential derivatives 14 and 15 with the introduction 
of a non-substituted pyrimidine moiety (IC50 values 0.233 µM and 0.106 µM), additional 
transformations should be accomplished that focus on the impact of replacing of CF3 with either EWG 
groups or ED functions. Also, the influence on the activity of further substituents on the phenyl ring 
was tested. In addition, further efforts were taken to determine the importance of introducing a 
methyl moiety on the pyrimidine heterocycle. Exploiting the earlier presented method, 16 analogues 
were prepared, with yields of up to 68% (Table 3). Except for 33 (besides the compound 14 and 15), 
all Betti-products were derived from the 4-methyl-2-amino-1,3-pyrimidine as amine input. The 
firstly-prepared 33, with a 4-CF3–C6H4 function on the R′′ position, demonstrated a slightly better 
effect in comparison with R′′ = C6H5 (14) or 4-NO2–C6H4 (15). Gratifyingly, the introduction of a 
methyl on the pyrimidine ring also increased the cytoprotection activity. For R′′ = 4-NO2–C6H4 (35), a 
similar IC50 value (0.114 µM) was observed. Replacing CF3 with SF5 (36) or halogenides such as 
fluorine (37), bromine (38), or iodine (39) slightly attenuated the efficiency. Interestingly, the 
combination of 4-chlorobenzaldehydes, 4-methyl-2-amino-pyrimidine, and 8-HQ afforded one of the 
most potent derivatives, 40, with a 73-nM IC50 value. Despite that, the 2,4- or 3,5-disubstituted phenyl 
moieties reduced the bioactivities; however, an acceptable cytoprotection level was provided by the 
incorporation of the 2,4-CF3–C6H3 group (compound 43, IC50 = 0.119 µM). Modification on the 
pyrimidine structure, replacing methyl into a bromine unit decreased the activity to 0.183 µM, while 
a solubility issue also occurred in that case. The presence of an electron-donating group on the R′′ 
position (analogue 47, IC50 = 0.481 µM) or a C-2 methyl function (derivative 48, IC50 = 0.887 µM) 
diminished the cytoprotective potential. 
According to our results, compounds 34, 35, 40, and 43 were proved to be the most potent 
pyrimidine derivatives and were selected for final assessment. 
Table 3. Functionalization with several pyrimidines (Subclass 3). 
 
Compounds Amine (R′) Aldehyde (R′′) R Yield (%) a IC50 (µM) SD 
33 
  
H 32 0.138 0.077 
34 
  
H 46 0.119 0.080 
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35 
  
H 19 0.114 0.095 
36 
  
H 68 0.140 0.152 
37 
 
 
H 16 0.163 0.109 
38 
 
 
H 18 0.149 0.067 
39 
  
H 29 0.135 0.098 
40 
  
H 40 0.073 0.021 
41 
 
 
H 31 0.169 0.129 
42 
  
H 59 0.413 0.240 
43 
  
H 16 0.119 0.050 
44 
 
 
H 25 0.139 0.064 
45 
  
H 15 0.313 0.067 
46 
  
H 15 0.183 0.157 
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47 
  
H 15 0.481 0.082 
48 
  
Me 25 0.887 0.226 
a after column chromatography and crystallization. 
2.3. Evaluation of the Most Active Compounds in a Real-Time Cytoprotection Assay 
In our primary assay, we have identified compounds that showed excellent activity. However, 
the derivatization of the basic scaffold with the combination of beneficial substitutions resulted in a 
handful of products with very similar activity and at the same time, significantly different 
modifications. Since the primary assay was unable to pinpoint one or two products that could be 
marked as leads, in an attempt to narrow down our selection of the most active compounds 
(compounds 4, 17, 18, 20, 21, 34, 35, 40, and 43 with IC50 between 0.08 and 0.12 µM) we have utilized 
an orthogonal assay to determine cytoprotective activity. Cell-based phenotypic screening, including 
end-point in vitro cellular screening protocols to identify cytoprotective compounds, are commonly 
used [44]; however, real-time cellular assays provide more information on the kinetics of drug action. 
Previously we have successfully adopted the RT-CES system to identify cytoprotective compounds 
[37]. Briefly, cells grown on golden electrodes in microplates were incubated with hydrogen peroxide 
alone or in the presence of our compounds. Using this system, cell viability can be monitored 
continuously with one-minute resolution through the measurement of impedance of the electrodes. 
The detected impedance is converted to an arbitrary measure (cell index) that is proportional to the 
number of attached cells, the strength of their attachment and cell morphology, since these properties 
influence electrode coverage. 
Using this real-time technique we have determined the IC50 values for each selected compound 
24 h after treatment. The calculated values were comparable to the ones determined in the primary 
assay, hence this assay was also unable to pinpoint a lead. Interestingly, the 4-CF3 and 4-methyl 
pyrimidine sidechain containing 34 performed the best with the lowest IC50 value, and significant 
effect (29% protection) at 110 nM concentration. Our least active compound, 48, bearing a methyl 
group in position 2 on the 8-HQ structure, also performed poorly in this assay. Results are 
summarized in Figure 3. 
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Figure 3. Real-time cytoprotection assay. (A): Real-time viability data traces of the most active 34 
analog were followed for 60 h after treatment. (B): Cytoprotective activity of the tested compounds 
24 h after treatment. Percentages were calculated in relation to non-treated and hydrogen peroxide-
only treated cell data. (C): Comparison of IC50 values determined from the primary (resazurin, end-
point) assay and the real time assay 24 h after treatment. 
2.4. Mitochondrial Membrane Depolarization following Oxidative Stress is Reversed by Treatment with the 
Novel 8-HQ Analogs 
Mitochondrial dysfunction is a prominent feature in neurodegenerative diseases, it can result in 
production and amplification of reactive oxygen species, and may be important in the 
pathophysiology of these diseases. Changes in the mitochondrial membrane potential (MMP) are 
detected in oxidative stress, and were suggested even as a biomarker for oxidative environmental 
stress [45]. 
The selected 10 most active analogues (compounds 4, 15, 17, 18, 20, 21, 34, 35, 40, and 43) were 
also tested as to whether they were able to reverse the mitochondrial membrane depolarization 
caused by the induced oxidative stress by hydrogen peroxide. The applied hydrogen peroxide 
treatment was higher in these experiments than in the previous assays (500 µM vs. 250 µM), in order 
to see a significant effect in the 2 h timeframe of this assay. All tested analogs effectively reversed the 
detected membrane depolarization. In this assay, the most active compounds (21, 34, and 43) were 
active even at the lowest applied 33 nM concentration. Figure 4 shows the effect of treatments 
compared to hydrogen peroxide treatment only (set by normalization as 1). 
 
Figure 4. Mitochondrial membrane depolarization assay. Treatment with the synthesized analogs 
reversed the mitochondrial membrane potential changes caused by oxidative stress. All data was 
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calculated by relation to hydrogen peroxide only treatment set to 1. Statistical significance (t-test): * p 
< 0.05 and ** p < 0.01. 
2.5. 8-HQ Analogues Induce Hypoxia Related Genes and Glucose Transporter Expression 
The contribution of cerebrovascular deficiencies (such as cerebral ischemia/stroke) and the 
dysregulation of brain insulin signaling have been strongly implicated in neurodegenerative diseases 
in recent years [46]. Reduction of blood supply leading to a hypoxic condition is known to activate 
cellular responses through hypoxia-inducible factors (HIFs). The stabilization of HIF1A protein 
controlling the expression of stress adaptation related genes is a major factor in the oxidative stress 
response [47]. Since our original 8-HQ analog (Q50, 21) showed potent activity in ischemic/reperfused 
myocardium in rats, it was selected along with a highly active (34) and less active compounds (47, 
48), and was investigated for its effect on oxidative stress response genes. Quantitative real-time PCR 
(qRT-PCR) analysis of the expression of oxidative stress-related genes HMOX-1, VEGF, and a glucose 
transporter GLUT1 was carried out. 
Results depicted in Figure 5 showed significant gene activation following treatment at 100 and 
300 nM concentrations in the case of 21 and 34, while gene-inducing capacity decreased parallel to 
cytoprotective activity with the less active compounds. 
 
Figure 5. Induction of hypoxia-related gene and glucose transporter expression. HIF1A-regulated 
genes were activated following treatment with selected analogs in a dose- and cytoprotective activity-
dependent manner. Statistical significance (t-test): * p < 0.05 and ** p < 0.01. 
3. Materials and Methods  
All NMR spectra were recorded in deuterated dimethyl sulfoxide (DMSO) at 298 K on a Bruker 
Avance 500 (Billerica, MA, USA) or Bruker Avance Neo 500 spectrometer (Billerica, MA, USA). All 
chemical shifts (δ) were reported in ppm relative to the residual solvent signal. HRMS spectra were 
recorded on a Thermo Scientific Q Exactive Plus mass spectrometer (Waltham, MA, USA) using a 
heated electrospray ionization (HESI-II) probe ion source. TLC was performed on aluminum sheets 
coated with silica gel 60 F254 (Merck, 1.05554, Budapest, Hungary). Visualization was done under 
UV light (254 nm). Column chromatography was carried out using silica gel (Merck, 60 Å, 0.063‒
0.200 mm, Budapest, Hungary). Melting points were determined by a Stuart SMP10 device 
(Staffordshire, UK), and they were uncorrected. All chemicals and solvents were of commercial grade 
and were used without further purification.  
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3.1. General Procedure for the Syntheses of Compounds 1–48 
To a solution of 1 mmol aldehyde, 3× volume of acetonitrile and 1 equivalent volume of amine 
were added to 0.6 equivalent of quinoline derivatives and 1% (v/v) formic acid. The reaction mixture 
was stirred at higher temperature (75 °C). The reaction was monitored by TLC (eluent: hexane 
isomeric mixture:acetone). If the product precipitated, it was filtered, washed with hexane, and dried. 
If the reaction mixture was homogeneous, it was evaporated to dryness and was purified by column 
chromatography (eluent: hexane:acetone from 20:1 to 4:1, v/v). The crude product was crystallized 
from hexane/ethyl-acetate. The molecular structures were determined by means of 1D and 2D-NMR 
technologies (see Supplementary Materials) 
7-(Phenyl(phenylamino)methyl)quinolin-8-ol (1): white solid, yield: 26% (51 mg), melting point (m.p.): 
141–143 °C, C22H18N2O; 1H-NMR (500 MHz, DMSO) δ 9.99 (s, 1H), 8.82 (s, 1H), 8.24 (d, J = 7.0 Hz, 1H), 
7.59 (d, J = 7.8 Hz, 1H), 7.53–7.48 (m, 1H), 7.43–7.38 (m, 2H), 7.35 (d, J = 7.9 Hz, 1H), 7.32–7.23 (m, 2H), 
7.24–7.14 (m, 1H), 7.01–6.92 (m, 2H), 6.67–6.59 (m, 2H), 6.49–6.42 (m, 2H), 6.14 (d, J = 5.3 Hz, 1H); 13C-
NMR (126 MHz, CDCl3) δ 149.77 (s), 148.25 (s), 147.97 (s), 142.87 (s), 138.11 (s), 136.04 (s), 128.75 (s), 
128.34 (s), 127.51 (s), 127.36 (s), 126.82 (s), 126.29 (s), 125.45 (s), 121.69 (s), 117.54 (s), 118.06 (s), 112.94 
(s), 54.16 (s); HRMS (ESI) m/z calcd. for C22H18N2O [M + H]+: 327.1492, found: 327.1493. 
7-((Phenylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (2): white solid, yield: 29% (69 mg), 
m.p.: 83–85 °C, C23H17F3N2O; 1H-NMR (500 MHz, DMSO) δ 10.14 (s, 1H), 8.84 (d, J = 2.2 Hz, 1H), 8.26 
(d, J = 8.2 Hz, 1H), 7.67 (d, J = 7.9 Hz, 2H), 7.62 (d, J = 7.8 Hz, 2H), 7.56 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 
7.7, 3.7 Hz, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.00 (t, J = 7.4 Hz, 2 H), 6.64 (d, J = 7.8 Hz, 2H), 6.55 (d, J = 6.9 
Hz, 1H), 6.50 (t, J = 7.0 Hz, 1H), 6.23 (d, J = 6.9 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 149.95 (s), 148.38 
(s), 147.73 (s), 147.68 (s), 138.14 (s), 136.09 (s), 128.84 (s), 128.09 (s), 127.71 (s), 127.53 (q, J = 31.9 Hz), 
126.16 (s), 125.29 (q, J = 3.3 Hz), 124.58 (s), 121.88 (s), 117.76 (s), 116.48 (s), 113.04 (s), 54.03 (s); HRMS 
(ESI) m/z calcd. for C23H17F3N2O [M + H]+: 395.1366, found: 395.1369. 
7-((Phenylamino)(pyridin-2-yl)methyl)quinolin-8-ol (3): white solid, yield: 13% (26 mg), m.p.: 129–130 °C, 
C21H17N3O; 1H-NMR (500 MHz, DMSO) δ 10.16 (s, 1H), 8.86 (dd, J = 4.2, 1.5 Hz, 1H), 8.56 (dd, J = 4.8, 
0.7 Hz, 1H), 8.25 (dd, J = 8.3, 1.5 Hz, 1H), 7.76 (td, J = 7.7, 1.8 Hz, 1H), 7.59–7.47 (m, 3H), 7.33 (d, J = 8.6 
Hz, 1H), 7.27 (ddd, J = 7.4, 5.0, 0.8 Hz, 1H), 7.02 (dd, J = 8.1, 7.6 Hz, 2H), 6.70 (d, J = 7.8 Hz, 2H), 6.61 
(d, J = 7.1 Hz, 1H), 6.50 (t, J = 7.3 Hz, 1H), 6.27 (d, J = 7.0 Hz, 1H); 13C-NMR (126 MHz, DMSO) δ 160.99 
(s), 150.53 (s), 149.30 (s), 148.69 (s), 147.80 (s), 138.59 (s), 137.43 (s), 136.48 (s), 129.28 (s), 128.05 (s), 
126.81 (s), 125.23 (s), 122.81 (s), 122.50 (s), 122.21 (s), 117.96 (s), 116.68 (s), 113.31 (s), 55.40 (s); HRMS 
(ESI) m/z calcd. for C21H17N3O [M + H]+: 328.1444, found: 328.1445. 
Ethyl 4-((4-fluorophenyl)(8-hydroxyquinolin-7-yl)methylamino)benzoate (4): white solid, yield: 17% (42 
mg), m.p.: 142–144 °C, C25H21FN2O3; 1H-NMR (500 MHz, DMSO) δ 10.17 (s, 1H), 8.87 (dd, J = 4.2, 1.5 
Hz, 1H), 8.30 (dd, J = 8.3, 1.5 Hz, 1H), 7.64 (d, J = 8.9 Hz, 2H), 7.56 (dd, J = 8.3, 4.2 Hz, 1H), 7.51 (d, J = 
8.6 Hz, 1H), 7.45–7.38 (m, 3H), 7.34 (d, J = 7.2 Hz, 1H), 7.20–7.14 (m, 2H), 6.69 (d, J = 8.8 Hz, 2H), 6.25 
(d, J = 7.2 Hz, 1H), 4.18 (q, J = 7.0 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H).; 13C-NMR (126 MHz, CDCl3) δ 165.78 
(s), 161.24 (d, J = 243.6 Hz), 151.80 (s), 150.01 (s), 148.42 (s), 138.11 (s), 136.11 (s), 130.78 (s), 129.38 (d, J 
= 8.1 Hz), 127.72 (s), 125.97 (s), 124.27 (s), 121.90 (s), 117.72 (s), 116.96 (s), 115.26 (s), 115.09 (s), 111.95 
(s), 59.58 (s), 53.35 (s), 14.34 (s). 
4-((4-Fluorophenyl)(8-hydroxyquinolin-7-yl)methylamino)benzoic acid (5): white solid, yield: 13% (30 mg), 
m.p.: 185–187 °C, C23H17FN2O3; 1H-NMR (500 MHz, DMSO) δ 12.01 (s, 1H), 10.22 (s, 1H), 8.85 (d, J = 
2.2 Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 7.9 Hz, 2H), 7.61 (d, J = 8.9 Hz, 2H), 7.59 (d, J = 8.4 Hz, 
2H), 7.54 (dd, J = 8.0, 3.9 Hz, 1H), 7.48 (d, J = 8.5 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.31 (d, J = 6.9 Hz, 
1H), 6.66 (d, J = 8.3 Hz, 2H), 6.31 (d, J = 6.7 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 167.37 (s), 151.48 
(s), 150.16 (s), 149.13 (d, J = 297.5 Hz), 148.49 (s), 146.83 (s), 138.14 (s), 136.14 (s), 131.02 (s), 128.20 (s), 
127.85 (s), 126.06 (s), 125.41 (d, J = 2.8 Hz), 123.73 (s), 122.01 (s), 118.04 (s), 117.84 (s), 111.92 (s), 53.82 
(s). 
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7-(Phenyl(pyridin-2-ylamino)methyl)quinolin-8-ol (6): white solid, yield: 25% (49 mg), m.p.: 172–174 °C, 
C21H17N3O; 1H-NMR (500 MHz, DMSO) δ 9.92 (s, 1H), 8.85 (dd, J = 4.0, 1.3 Hz, 1H), 8.29 (dd, J = 8.3, 
1.1 Hz, 1H), 7.92 (d, J = 4.1 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.54 (dd, J = 8.3, 4.2 Hz, 1H), 7.42–7.34 (m, 
5 H), 7.29 (t, J = 7.6 Hz, 2 H), 7.20 (t, J = 7.3 Hz, 1 H), 6.86 (d, J = 8.5 Hz, 1 H), 6.68 (d, J = 8.4 Hz, 1 H), 
6.55–6.37 (m, 1H); 13C-NMR (126 MHz, DMSO) δ 158.43 (s), 150.00 (s), 148.69 (s), 147.90 (s), 144.00 (s), 
138.57 (s), 137.12 (s), 136.47 (s), 128.62 (s), 127.86 (s), 127.66 (s), 127.04 (s), 126.95 (s), 126.36 (s), 122.05 
(s), 117.73 (s), 112.51 (s), 109.26 (s), 52.08 (s); HRMS (ESI) m/z calcd. for C21H17N3O [M + H]+: 328.1444, 
found: 328.1447. 
7-(Isoxazol-3-ylamino)(pyridin-2-yl)methyl)quinolin-8-ol (7): white solid, yield: 27% (52 mg), m.p.: 145–
146 °C, C18H14N4O2; 1H-NMR (500 MHz, DMSO) δ 10.02 (s, 1H), 8.82 (d, J = 2.1 Hz, 1H), 8.49 (d, J = 3.4 
Hz, 1H), 8.31 (bs, 1H), 8.24 (d, J = 8.1 Hz, 1H), 7.73 (t, J = 7.5 Hz, 1H), 7.54 (d, J = 8.5 Hz, 1H), 7.52–7.46 
(m, 2H), 7.33 (d, J = 8.5 Hz, 1H), 7.27–7.12 (m, 2H), 6.35 (d, J = 7.9 Hz, 1H), 6.09 (bs, 1H); 13C-NMR (126 
MHz, CDCl3) δ 162.79 (s), 160.56 (s), 158.17 (s), 149.88 (s), 148.84 (s), 148.23 (s), 138.14 (s), 136.83 (s), 
136.00 (s), 127.57 (s), 126.24 (s), 124.61 (s), 122.27 (s), 121.81 (s), 121.73 (s), 117.23 (s), 97.02 (s), 55.73 (s); 
HRMS (ESI) m/z calcd. for C18H14N4O2 [M + H]+: 319.1190, found: 319.1189. 
7-((5-tert-Butylisoxazol-3-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (8): white solid, yield: 
18% (48 mg), m.p.: 185–187 °C, C24H22F3N3O2; 1H-NMR (500 MHz, DMSO) δ 10.08 (s, 1H), 8.84 (bs, 
1H), 8.28 (d, J = 8.2 Hz, 1H), 7.66 (d, J = 7.8 Hz, 2H), 7.59–7.50 (m, 4H), 7.40 (d, J = 8.4 Hz, 1H), 7.10 (d, 
J = 7.8 Hz, 1H), 6.31 (d, J = 7.7 Hz, 1H), 5.66 (s, 1H), 1.18 (s, 9H); 13C-NMR (126 MHz, DMSO) δ 179.26 
(s), 163.57 (s), 150.17 (s), 148.89 (s), 148.27 (s), 138.57 (s), 136.54 (s), 128.11 (s), 127.84 (q, J = 31.9 Hz), 
126.38 (s), 125.69 (q, J = 3.9 Hz), 124.93 (s), 124.78 (q, J = 272.2 Hz), 122.35 (s), 118.05 (s), 91.12 (s), 54.54 
(s), 32.63 (s), 28.89 (s); HRMS (ESI) m/z calcd. for C24H22F3N3O2 [M + H]+: 442.1737, found: 442.1739. 
7-((4-Fluorophenyl)(5-methylisoxazol-3-ylamino)methyl)quinolin-8-ol (9): white solid, yield: 13% (27 mg), 
m.p.: 153–155 °C, C20H16FN3O2; 1H-NMR (500 MHz, DMSO) δ 9.98 (s, 1H), 8.86 (dd, J = 3.9, 1.1 Hz, 
1H), 8.30 (d, J = 8.3 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.55 (dd, J = 8.3, 4.2 Hz, 1H), 7.41 (d, J = 8.7 Hz, 
1H), 7.38 (dd, J = 8.4, 5.9 Hz, 2H), 7.13 (t, J = 8.8 Hz, 2H), 7.01 (d, J = 8.3 Hz, 1H), 6.23 (d, J = 8.3 Hz, 
1H), 5.73 (s, 1H), 2.20 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 167.92 (s), 164.03 (s), 161.48 (d, J = 242.6 
Hz), 149.95 (s), 148.76 (s), 139.56 (s), 138.55 (s), 136.49 (s), 129.32 (d, J = 8.1 Hz), 127.96 (s), 126.27 (s), 
125.66 (s), 122.18 (s), 117.87 (s), 115.36 (d, J = 21.2 Hz), 94.33 (s), 54.21 (s), 12.45 (s); HRMS (ESI) m/z 
calcd. for C20H16FN3O2 [M + H]+: 350.1299, found: 350.1300. 
7-((5-Methylisoxazol-3-ylamino)(4-nitrophenyl)methyl)quinolin-8-ol (10): white solid, yield: 26% (59 mg), 
o.p.: 138–140 °C, C20H16N4O4; 1H-NMR (500 MHz, DMSO) δ 10.16 (s, 1H), 8.84 (s, 1H), 8.28 (d, J = 8.1 
Hz, 1H), 8.16 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 8.1 Hz, 2H), 7.56–7.48 (m, 2H), 7.40 (d, J = 8.4 Hz, 1H), 7.15 
(d, J = 7.7 Hz, 1H), 6.34 (d, J = 7.7 Hz, 1H), 5.74 (s, 1H), 2.18 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 
167.76 (s), 163.53 (s), 150.90 (s), 149.77 (s), 148.49 (s), 146.35 (s), 138.15 (s), 136.10 (s), 128.01 (s), 127.77 
(s), 125.93 (s), 124.02 (s), 123.56 (s), 122.00 (s), 117.73 (s), 93.91 (s), 54.18 (s), 12.01 (s); HRMS (ESI) m/z 
calcd. for C20H16N4O4 [M + H]+: 377.1244, found: 377.1250. 
7-((4-Fluorophenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (11): white solid, yield: 12% (26 mg), 
m.p.: 157–159 °C, C22H18FN3O; 1H-NMR (500 MHz, DMSO) δ 9.97 (s, 1H), 8.82 (d, J = 2.5 Hz, 1H), 8.26 
(d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.50 (dd, J = 8.1, 4.0 Hz, 1H), 7.41–7.31 (m, 3H), 7.30–7.17 
(m, 2H), 7.08 (t, J = 8.7 Hz, 2H), 6.80 (d, J = 8.4 Hz, 1H), 6.40 (t, J = 12.7 Hz, 1H), 6.33 (d, J = 6.9 Hz, 1H), 
2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 160.92 (d, J = 242.0 Hz), 157.50 (s), 155.70 (s), 149.53 (s), 
148.29 (s), 139.82 (s), 138.13 (s), 137.24 (s), 136.04 (s), 128.95 (d, J = 8.0 Hz), 127.48 (s), 126.60 (s), 125.68 
(s), 121.68 (s), 117.43 (s), 114.84 (d, J = 21.2 Hz), 111.29 (s), 105.17 (s), 51.11 (s), 24.23 (s); HRMS (ESI) 
m/z calcd. for C22H18FN3O [M + H]+: 360.1507, found: 360.1508. 
7-((4-Isopropoxyphenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (12): white solid, yield: 25% (60 
mg), m.p.: 132–134 °C, C25H25N3O2; 1H-NMR (500 MHz, DMSO) δ 9.80 (d, J = 117.5 Hz, 1H), 8.85 (dd, 
J = 4.1, 1.4 Hz, 1H), 8.29 (dd, J = 8.3, 1.3 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.53 (dd, J = 8.3, 4.2 Hz, 1H), 
7.40 (d, J = 8.6 Hz, 1H), 7.26 (t, J = 8.2 Hz, 3H), 7.16 (d, J = 8.9 Hz, 1H), 6.82 (d, J = 8.7 Hz, 2H), 6.73 (d, 
J = 8.7 Hz, 1H), 6.41 (d, J = 8.3 Hz, 1H), 6.34 (d, J = 7.1 Hz, 1H), 4.53 (h, J = 6.0 Hz, 1H), 2.22 (s, 3H), 1.22 
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(d, J = 6.0 Hz, 6H); 13C-NMR (126 MHz, DMSO) δ 158.05 (s), 156.55 (s), 156.12 (s), 149.85 (s), 148.66 (s), 
138.57 (s), 137.64(s), 136.45 (s), 135.71 (s), 128.73 (s), 127.80 (s), 127.12 (s), 126.66 (s), 122.00 (s), 117.73 
(s), 115.62 (s), 111.54 (s), 105.42 (s), 69.45 (s), 51.58 (s), 24.68 (s), 22.33 (s); HRMS (ESI) m/z calcd. for 
C25H25N3O2 [M + H]+: 400.2020, found: 400.2018. 
7-((6-Methylpyridin-2-ylamino)(pyridin-2-yl)methyl)quinolin-8-ol (13): white solid, yield: 16% (33 mg), 
m.p.: 170–173 °C, C21H18N4O; 1H-NMR (500 MHz, DMSO) δ 10.12 (s, 1H), 8.82 (s, 1H), 8.49 (s, 1H), 
8.23 (d, J = 7.9 Hz, 1H), 7.71 (t, J = 7.1 Hz, 1H), 7.55–7.44 (m, 3H), 7.31 (d, J = 8.3 Hz, 1H), 7.27–7.18 (m, 
3H), 6.76 (d, J = 7.1 Hz, 1H), 6.40 (t, J = 17.7 Hz, 1H), 6.33 (d, J = 6.7 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 
MHz, CDCl3) δ 161.06 (s), 157.24 (s), 155.73 (s), 149.93 (s), 148.71 (s), 148.25 (s), 138.24 (s), 137.33 (s), 
136.80 (s), 135.99 (s), 127.55 (s), 126.75 (s), 125.22 (s), 122.13 (s), 121.96 (s), 121.68 (s), 117.34 (s), 111.37 
(s), 104.91 (s), 53.29 (s), 24.15 (s); HRMS (ESI) m/z calcd. for C21H18N4O [M + H]+: 343.1553, found: 
343.1555. 
7-(Phenyl(pyrimidin-2-ylamino)methyl)quinolin-8-ol (14): white solid, yield: 15% (30 mg), m.p.: 192–195 
°C, C20H16N4O; 1H-NMR (500 MHz, DMSO) δ 9.98 (s, 1H), 8.85 (d, J = 2.9 Hz, 1H), 8.33–8.27 (m, 3H), 
8.08 (d, J = 9.4 Hz, 1H), 7.76 (d, J = 8.5 Hz, 1H), 7.54 (dd, J = 8.2, 4.1 Hz, 1H), 7.44–7.36 (m, 3H), 7.28 (t, 
J = 7.6 Hz, 2H), 7.19 (t, J = 7.3 Hz, 1H), 7.00 (d, J = 9.4 Hz, 1H), 6.60 (t, J = 4.7 Hz, 1H); 13C-NMR (126 
MHz, DMSO) δ 162.17 (s), 158.51 (s), 149.91 (s), 148.72 (s), 143.59 (s), 138.51 (s), 136.49 (s), 128.63 (s), 
127.92 (s), 127.49 (s), 127.33 (s), 127.01 (s), 125.81 (s), 122.13 (s), 117.79 (s), 111.07 (s), 52.31 (s); HRMS 
(ESI) m/z calcd. for C20H16N4O [M + H]+: 329.1397, found: 329.1397. 
7-((4-Nitrophenyl)(pyrimidin-2-ylamino)methyl)quinolin-8-ol (15): yellow solid, yield: 40% (90 mg), m.p.: 
121–123 °C, C20H15N5O3; 1H-NMR (500 MHz, DMSO) δ 10.17 (s, 1H), 8.84 (d, J = 2.4 Hz, 1H), 8.29 (dd, 
J = 8.7, 6.1 Hz, 3H), 8.23 (d, J = 9.0 Hz, 1H), 8.15 (d, J = 8.4 Hz, 2H), 7.69 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 
8.4 Hz, 2H), 7.53 (dd, J = 8.0, 3.9 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 9.0 Hz, 1H), 6.62 (t, J = 4.3 
Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 161.62 (s), 158.17 (s), 151.08 (s), 149.79 (s), 148.46 (s), 146.32 (s), 
138.11 (s), 136.11 (s), 128.16 (s), 127.79 (s), 126.68 (s), 123.95 (s), 123.56 (s), 121.96 (s), 117.69 (s), 111.07 
(s), 51.78 (s); HRMS (ESI) m/z calcd. for C20H15N5O3 [M + H]+: 374.1248, found: 374.1250. 
Ethyl 4-((8-hydroxyquinolin-7-yl)(4-(trifluoromethyl)phenyl)methylamino)benzoate (16): white solid, yield: 
30% (84 mg), m.p.: 95–98 °C, C26H21F3N2O3; 1H-NMR (500 MHz, DMSO) δ 10.27 (s, 1H), 8.88 (dd, J = 
4.1, 1.2 Hz, 1H), 8.31 (dd, J = 8.3, 1.1 Hz, 1H), 7.72 (d, J = 8.3 Hz, 2H), 7.66 (d, J = 8.7 Hz, 2H), 7.61 (d, J 
= 8.2 Hz, 2H), 7.57 (dd, J = 8.3, 4.2 Hz, 1H), 7.50 (d, J = 8.6 Hz, 1H), 7.44–7.39 (m, 2H), 6.71 (d, J = 8.7 
Hz, 2H), 6.35 (d, J = 7.1 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H); 13C-NMR (126 MHz, 
DMSO) δ 166.21 (s), 152.16 (s), 150.63 (s), 148.95 (s), 147.18 (s), 138.58 (s), 136.59 (s), 131.27 (s), 128.63 
(s), 128.30 (s), 128.12–127.65(m), 126.48 (s), 125.87 (q, J = 3.2 Hz), 124.07 (s), 122.47 (s), 118.28 (s), 117.62 
(s), 112.46 (s), 60.06 (s), 54.22 (s), 14.78 (s); HRMS (ESI) m/z calcd. for C26H21F3N2O3 [M + H]+: 467.1577, 
found: 467.1584. 
Ethyl 4-((8-hydroxyquinolin-7-yl)(pyridin-2-yl)methylamino)benzoate (17): white solid, yield: 60% (144 
mg), m.p.: 157–159 °C, C24H21N3O3; 1H-NMR (500 MHz, DMSO) δ 10.22 (s, 1H), 8.84 (s, 1H), 8.54 (s, 
1H), 8.23 (d, J = 8.1 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.62 (d, J = 8.0 Hz, 2H), 7.53–7.50 (m, 1H), 7.48 (d, 
J = 8.3 Hz, 2H), 7.42 (d, J = 6.5 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.28–7.22 (m, 1H), 6.73 (d, J = 7.9 Hz, 
2H), 6.34 (d, J = 6.5 Hz, 1H), 4.14 (q, J = 6.8 Hz, 2H), 1.20 (t, J = 6.6 Hz, 3H); 13C-NMR (126 MHz, CDCl3) 
δ 165.77 (s), 159.85 (s), 151.43 (s), 150.19 (s), 148.99 (s), 148.35 (s), 138.14 (s), 137.11 (s), 136.06 (s), 130.79 
(s), 127.73(s), 126.24 (s), 123.92 (s), 122.56 (s), 122.11 (s), 121.89 (s), 117.63 (s), 116.94 (s), 111.95 (s), 59.58 
(s), 54.84 (s), 14.33 (s); HRMS (ESI) m/z calcd. for C24H21N3O3 [M + H]+: 400.1656, found: 400.1661. 
7-(Pyridin-2-yl(4-(trifluoromethyl)phenylamino)methyl)quinolin-8-ol (18): white solid, yield: 33% (78 mg), 
m.p.: 162–164 °C, C22H16F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.22 (s, 1H), 8.84 (d, J = 3.4 Hz, 1H), 
8.55 (d, J = 4.0 Hz, 1H), 8.23 (d, J = 8.2 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.54–7.47 (m, 3H), 7.34–7.30 (m, 
4H), 7.29–7.23 (m, 1H), 6.79 (d, J = 8.2 Hz, 2H), 6.31 (d, J = 6.8 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 
160.33 (s), 150.95 (s), 150.80 (s), 149.54 (s), 148.80 (s), 138.55 (s), 137.57 (s), 136.53 (s), 128.18 (s), 126.65 
(s), 126.61 (s), 125.71 (q, J = 269.9 Hz), 124.33 (s), 123.01 (s), 122.57 (s), 122.33 (s), 118.10 (s), 116.35 (q, J 
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= 31.8 Hz), 112.68 (s), 55.33 (s); HRMS (ESI) m/z calcd. for C22H16F3N3O [M + H]+: 396.1318, found: 
396.1323. 
7-((3-Fluoro-4-(trifluoromethyl)phenyl)(morpholino)methyl)quinolin-8-ol7-((4-nitrophenylamino) (pyridin-
2-yl)methyl)quinolin-8-ol (19): yellow-green (viridian) solid, yield: 14% (31 mg), m.p.: 128–131 °C, 
C21H16N4O3; 1H-NMR (500 MHz, DMSO) δ 10.32 (s, 1H), 8.87–8.83 (m, 1H), 8.57 (d, J = 3.1 Hz, 1H), 
8.25 (d, J = 8.2 Hz, 1H), 8.12 (d, J = 6.6 Hz, 1H), 7.94 (d, J = 8.6 Hz, 2H), 7.77 (t, J = 7.6 Hz, 1H), 7.53 (dd, 
J = 7.8, 3.8 Hz, 1H), 7.50–7.41 (m, 2H), 7.34 (d, J = 8.5 Hz, 1H), 7.31–7.25 (m, 1H), 6.78 (bs, 2H), 6.39 (d, 
J = 6.7 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 159.21 (s), 153.27 (s), 150.30 (s), 149.11 (s), 148.46 (s), 
138.14 (s), 137.25 (s), 136.43 (s), 136.11 (s), 127.87 (s), 126.09 (s), 126.03 (s), 123.23 (s), 122.76 (s), 122.21 
(s), 122.03 (s), 117.77 (s), 55.15 (s); HRMS (ESI) m/z calcd. for C21H16N4O3 [M + H]+: 373.1295, found: 
373.1299. 
7-((6-Methylpyridin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (20): white solid, yield: 
33% (81 mg), m.p.: 147–150 °C, C23H18F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.06 (s, 1H), 8.83 (bs, 1H), 
8.27 (d, J = 8.0 Hz, 1H), 7.66–7.59 (m, 3H), 7.56 (d, J = 7.4 Hz, 2H), 7.52 (d, J = 2.7 Hz, 1H), 7.40 (d, J = 
8.3 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.26 (t, J = 7.1 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 6.46 (d, J = 8.0 Hz, 
1H), 6.35 (d, J = 6.6 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.41 (s), 155.70 (s), 149.70 (s), 
148.68 (s), 148.38 (s), 138.15 (s), 137.27 (s), 136.07 (s), 127.79 (s), 127.62 (s), 127.16 (q, J = 31.7 Hz), 126.67 
(s), 125.11 (dd, J = 6.9, 3.8 Hz), 124.96 (s), 124.39 (q, J = 271.7 Hz), 121.81 (s), 117.57 (s), 111.44 (s), 105.41 
(s), 52.20 (s), 24.24 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O [M + H]+: 410.1475, found: 410.1478. 
7-((6-Methylpyridin-2-ylamino)(4-nitrophenyl)methyl)quinolin-8-ol (21): pale yellow solid, yield: 51% 
(118 mg), m.p.: 159–161 °C, C22H18N4O3; 1H-NMR (500 MHz, DMSO) δ 10.13 (s, 1H), 8.84 (d, J = 2.8 Hz, 
1H), 8.28 (d, J = 8.1 Hz, 1H), 8.15 (d, J = 8.5 Hz, 2H), 7.64–7.56 (m, 3H), 7.53 (dd, J = 8.1, 4.0 Hz, 1H), 
7.40 (t, J = 8.4 Hz, 2H), 7.33–7.19 (m, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.47 (d, J = 8.2 Hz, 1H), 6.36 (d, J = 7.1 
Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.28 (s), 155.70 (s), 151.99 (s), 149.79 (s), 148.45 
(s), 146.17 (s), 138.16 (s), 137.30 (s), 136.10 (s), 128.14 (s), 127.72 (s), 126.66 (s), 124.48 (s), 123.48 (s), 
121.92 (s), 117.67 (s), 111.56 (s), 105.57 (s), 51.47 (s), 24.24 (s); HRMS (ESI) m/z calcd. for C22H18N4O3 [M 
+ H]+: 387.1452, found: 387.1451. 
2-Methyl-7-((6-methylpyridin-2-ylamino)(4-nitrophenyl)methyl)quinolin-8-ol (22): ivory-white solid, 
yield: 23% (55 mg), m.p.: 134–136 °C, C23H20N4O3; 1H-NMR (500 MHz, DMSO) δ 9.64 (s, 1H), 8.20–8.10 
(m, 3H), 7.62 (d, J = 8.7 Hz, 2H), 7.53 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.41 (d, J = 8.6 Hz, 1H), 
7.37 (d, J = 8.5 Hz, 1H), 7.30 (dd, J = 8.0, 7.4 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 6.50 (d, J = 8.3 Hz, H), 6.39 
(d, J = 7.2 Hz, 1 H), 2.69 (d, J = 10.1 Hz, 3H), 2.22 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 157.73 (s), 
157.60 (s), 156.12 (s), 152.53 (s), 149.34 (s), 146.59 (s), 137.87 (s), 137.74 (s), 136.58 (s), 128.52 (s), 126.23 
(s), 125.95 (s), 124.69 (s), 123.91 (s), 123.17 (s), 117.96 (s), 111.99 (s), 106.04 (s), 51.87 (s), 25.16 (s), 24.69 
(s); HRMS (ESI) m/z calcd. for C23H20N4O3 [M + H]+: 401.1608, found: 401.1609. 
2-Methyl-7-((6-methylpyridin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (23): beige solid, 
yield: 71% (180 mg), m.p.: 122–124 °C, C24H20F3N3O; 1H-NMR (500 MHz, DMSO) δ 9.54 (s, 1H), 8.15 
(d, J = 8.4 Hz, 1H), 7.82 (d, J = 3.9 Hz, 1H), 7.65–7.59 (m, 3H), 7.55 (d, J = 7.9 Hz, 2H), 7.39 (d, J = 8.4 Hz, 
1H), 7.33 (d, J = 8.5 Hz, 1H), 7.27 (d, J = 6.7 Hz, 1H), 7.07 (t, J = 18.0 Hz, 1H), 6.54–6.43 (m, 2H), 2.67 (s, 
3H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.02 (s), 155.79 (s), 149.05 (s), 148.68 (s), 144.77 (s), 
137.48 (s), 136.92 (s), 136.10 (s), 127.85 (s), 127.08 (dd, J = 63.3, 31.6 Hz), 126.25 (s), 125.75 (s), 124.97 
(dd, J = 6.8, 3.8 Hz), 124.64 (s), 124.42 (q, J = 271.9 Hz), 122.59 (s), 117.34 (s), 117.14 (s), 112.75 (s), 52.45 
(s), 24.69 (s), 16.92 (s); HRMS (ESI) m/z calcd. for C24H20F3N3O [M + H]+: 424.1631, found: 424.1631. 
7-((6-Methylpyridin-2-ylamino)(4-(trifluoromethoxy)phenyl)methyl)quinolin-8-ol (24): white solid, yield: 
34% (87 mg), m.p.: 99–101 °C, C23H18F3N3O2; 1H-NMR (500 MHz, DMSO) δ 10.00 (s, 1H), 8.82 (d, J = 
2.0 Hz, 1H), 8.27 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.51 (dd, J = 7.6, 3.6 Hz, 1H), 7.45 (d, J = 8.1 
Hz, 2H), 7.39 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 7.28–7.21 (m, 3H), 6.86 (d, J = 8.2 Hz, 1H), 6.43 
(d, J = 8.1 Hz, 1H), 6.34 (d, J = 6.9 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.44 (s), 155.70 
(s), 149.71 (s), 148.31 (s), 146.90 (s), 143.21 (s), 138.17 (s), 137.25 (s), 136.05 (s), 128.89 (s), 127.57 (s), 
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126.57 (s), 125.30 (s), 121.73 (s), 120.78 (s), 117.42 (s), 116.02 (d, J = 260.6 Hz), 111.35 (s), 105.28 (s), 51.14 
(s), 24.24 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O2 [M + H]+: 426.1424, found: 426.1423. 
7-((6-Methylpyridin-2-ylamino)(3-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (25): white solid, yield: 
62% (152 mg), m.p.: 148–152 °C, C23H18F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.07 (s, 1H), 8.83 (s, 1H), 
8.27 (d, J = 8.2 Hz, 1H), 7.71 (s, 1H), 7.69–7.60 (m, 2H), 7.56–7.46 (m, 3H), 7.44–7.35 (m, 2H), 7.27 (t, J = 
7.6 Hz, 1H), 6.93 (d, J = 8.6 Hz, 1H), 6.45 (d, J = 8.2 Hz, 1H), 6.35 (d, J = 6.9 Hz, 1H), 2.19 (s, 3H); 13C-
NMR (126 MHz, CDCl3) δ 157.37 (s), 155.70 (s), 149.67 (s), 148.41 (s), 145.29 (s), 138.12 (s), 137.32 (s), 
136.08 (s), 131.32 (s), 129.29 (s), 128.88 (d, J = 31.4 Hz), 127.60 (s), 126.44 (s), 125.22 (q, J = 48.0 Hz), 
125.03 (s), 123.34 (s), 121.82 (s), 117.62 (s), 111.49 (s), 105.40 (s), 51.40 (s), 24.21 (s); HRMS (ESI) m/z 
calcd. for C23H18F3N3O [M + H]+: 410.1475, found: 410.1476. 
7-((3-Methylpyridin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (26): white solid, yield: 
18% (44 mg), m.p.: 148–151 °C, C23H18F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.09 (s, 1H), 8.83 (d, J = 
3.1 Hz, 1H), 8.28 (d, J = 8.2 Hz, 1H), 7.81 (d, J = 4.1 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 7.9 Hz, 
2 H), 7.58–7.48 (m, 3H), 7.39 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 6.7 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 6.53–
6.45 (m, 2H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 155.75 (s), 149.93 (s), 148.57 (s), 148.34 (s), 
144.73 (s), 138.18 (s), 136.95 (s), 136.06 (s), 127.93 (s), 127.67 (s), 127.32 (s), 127.10 (q, J = 31.3 Hz), 125.00 
(q, J = 2.9 Hz), 124.88 (s), 124.42 (q, J = 272.0 Hz), 121.79 (s), 117.48 (s), 117.17 (s), 112.75 (s), 52.33 (s), 
16.95 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O [M + H]+: 410.1475, found: 410.1479. 
7-((4-Methylpyridin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (27): mulatto solid, yield: 
15% (37 mg), m.p.: 151–153 °C, C23H18F3N3O; 1H-NMR (500 MHz, DMSO) δ 10.06 (s, 1H), 8.86 (dd, J = 
4.1, 1.4 Hz, 1H), 8.30 (dd, J = 8.3, 1.3 Hz, 1H), 7.80 (d, J = 5.2 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.59 (d, J 
= 8.5 Hz, 1H), 7.57–7.53 (m, 3H), 7.42 (d, J = 8.6 Hz, 1H), 7.37 (d, J = 8.4 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 
6.54 (s, 1H), 6.36 (d, J = 5.1 Hz, 1H), 2.15 (s, H); 13C-NMR (126 MHz, DMSO) δ 158.49 (s), 150.16 (s), 
149.13 (s), 148.81 (s), 147.58 (s), 147.46 (s), 138.59 (s), 136.52 (s), 128.27 (s), 128.05 (s), 127.60 (q, J = 31.5 
Hz), 127.03 (s), 125.58(q, J = 3.5 Hz), 125.49 (s), 124.83 (q, J = 271.6 Hz), 122.24 (s), 117.96 (s), 114.48 (s), 
109.35 (s), 51.91 (s), 21.09 (s); HRMS (ESI) m/z calcd. for C23H18F3N3O [M + H]+: 410.1475, found: 
410.1477. 
7-((3-Fluoro-5-(trifluoromethyl)phenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (28): white solid, 
yield: 35% (90 mg), m.p.: 163–165 °C, C23H17F4N3O; 1H-NMR (500 MHz, DMSO) δ 10.19 (s, 1H), 8.87 
(dd, J = 4.0, 1.2 Hz, 1H), 8.31 (dd, J = 8.3, 1.1 Hz, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.60 (s, 1H), 7.56 (dd, J = 
8.3, 4.2 Hz, 1H), 7.51 (d, J = 9.2 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 7.31 (t, J = 7.7 Hz, 1H), 6.95 (d, J = 8.7 
Hz, 1H), 6.50 (d, J = 8.3 Hz, 1H), 6.40 (d, J = 7.2 Hz, 1H), 2.22 (s, 3H); 13C NMR (126 MHz, DMSO) δ 
162.40 (d, J = 246.4 Hz), 157.62 (s), 156.15 (s), 150.19 (s), 149.34 (d, J = 6.8 Hz), 148.95 (s), 138.57 (s), 
137.84 (s), 136.57 (s), 131.17 (qd, J = 32.7, 8.7 Hz), 128.16 (s), 126.69 (s), 124.86 (s), 123.82 (dq, J = 272.8, 
2.6 Hz), 122.40 (s), 120.30–120.02 (m), 118.39 (d, J = 21.8 Hz), 118.22 (s), 112.16 (s), 111.39 (dq, J = 25.1, 
3.4 Hz), 106.01 (s), 51.75 (s), 24.64 (s); HRMS (ESI) m/z calcd. for C23H17F4N3O [M + H]+: 428.1381, 
found: 428.1388. 
7-((3,5-bis(Trifluoromethyl)phenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (29): white solid, 
yield: 43% (123 mg), m.p.: 144–146 °C, C24H17F6N3O; 1H-NMR (500 MHz, DMSO) δ 10.20 (s, 1H), 8.84 
(bs, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.03 (s, 2H), 7.92 (s, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.58–7.48 (m, 2H), 
7.43 (d, J = 8.4 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H), 6.98 (d, J = 8.3 Hz, 1H), 6.48 (d, J = 8.1 Hz, 1H), 6.38 (d, 
J = 6.9 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.12 (s), 155.69 (s), 149.81 (s), 148.56 (s), 
147.44 (s), 138.11 (s), 137.44 (s), 136.13 (s), 130.08 (q, J = 32.3 Hz), 127.78 (s), 127.68 (s), 126.08 (s), 124.14 
(s), 123.39 (q, J = 272.5 Hz), 122.01 (s), 120.48 (s), 117.87 (s), 111.83 (s), 105.67 (s), 51.55 (s), 24.13 (s); 
HRMS (ESI) m/z calcd. for C24H17F6N3O [M + H]+: 478.1349, found: 478.1353. 
7-((4-Fluoro-3-(trifluoromethyl)phenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (30): white solid, 
yield: 90% (231 mg), m.p.: 148–151 °C, C23H17F4N3O; 1H-NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 8.83 
(s, 1H), 8.27 (d, J = 8.1 Hz, 1H), 7.73 (d, J = 6.2 Hz, 1H), 7.65 (d, J = 8.7 Hz, 2H), 7.52 (dd, J = 8.0, 3.9 Hz, 
1H), 7.45–7.36 (m, 3H), 7.27 (t, J = 7.7 Hz, 1H), 6.87 (d, J = 8.5 Hz, 1H), 6.44 (t, J = 9.4 Hz, 1H), 6.34 (t, J 
= 15.0 Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 159.53–156.77 (m), 157.71 (s), 156.16 (s), 
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150.13 (s), 148.90 (s), 141.39 (d, J = 3.4 Hz), 138.55 (s), 137.76 (d, J = 13.0 Hz), 136.55 (s), 134.27 (d, J = 
8.5 Hz), 129.47–121.35 (m), 128.10(s), 126.68 (s), 125.77 (q, J = 4.7 Hz), 125.26 (s), 122.31 (s), 118.12 (s), 
117.48 (d, J = 20.4 Hz), 116.78–116.78 (m), 112.03 (s), 105.88 (s), 51.42 (s), 24.65 (s); HRMS (ESI) m/z 
calcd. for C23H17F4N3O [M + H]+: 428.1381, found: 428.1385. 
7-((2,4-bis(Trifluoromethyl)phenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (31): light rose solid, 
yield: 22% (63 mg), m.p.: decomposed 230 °C, C24H17F6N3O; 1H-NMR (500 MHz, DMSO) δ 9.83 (s, 
1H), 8.87 (d, J = 2.9 Hz, 1H), 8.33 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 8.2 Hz, 1H), 8.11 (d, J = 8.2 Hz, 1H), 
8.01 (s, 1H), 7.63 (dd, J = 8.6, 4.1 Hz, 1H), 7.59 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.25 (t, J = 7.7 
Hz, 1H), 6.92 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 8.0 Hz, 1H), 6.37 (d, J = 7.2 Hz, 1H), 2.17 (s, 3H); HRMS 
(ESI) m/z calcd. for C24H17F6N3O [M + H]+: 478.1349, found: 478.1356. 
7-((3,4-Difluorophenyl)(6-methylpyridin-2-ylamino)methyl)quinolin-8-ol (32): white solid, yield: 53% (120 
mg), m.p.: 175–178 °C, C22H17F2N3O; 1H-NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 8.86 (dd, J = 4.0, 1.2 
Hz, 1H), 8.30 (dd, J = 8.2, 1.1 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.55 (dd, J = 8.3, 4.2 Hz, 1H), 7.42 (d, J = 
8.6 Hz, 1H), 7.40–7.27 (m, 4 H), 7.24–7.15 (m, 1H), 6.83 (d, J = 8.8 Hz, 1H), 6.46 (d, J = 8.3 Hz, 1H), 6.38 
(d, J = 7.2 Hz, 1H), 2.26 (d, J = 40.6 Hz, 3H); 13C-NMR (126 MHz, CDCl3) δ 157.32 (s), 155.72 (s), 149.61 
(s), 149.19 (dd, J = 245.7, 13.0 Hz), 148.38 (s), 148.09 (dd, J = 244.0, 13.1 Hz), 141.68 (s), 138.14 (s), 137.30 
(s), 136.07 (s),127.59 (s), 126.43 (s), 125.08 (s), 123.70 (s), 121.80 (s), 117.58 (s), 117.16 (d, J = 16.9 Hz), 
115.74 (d, J = 17.3 Hz), 111.50 (s), 105.33 (s), 50.96 (s), 24.22 (s); HRMS (ESI) m/z calcd. for C22H17F2N3O 
[M + H]+: 378.1412, found: 378.1413. 
7-((Pyrimidin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (33): white solid, yield: 32% (76 
mg), m.p.: 160–163 °C, C21H15F3N4O; 1H-NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 8.83 (d, J = 2.3 Hz, 
1H), 8.33–8.23 (m, 3H), 8.18 (d, J = 9.1 Hz, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.64 (d, J = 7.9 Hz, 2H), 7.57 (d, 
J = 7.8 Hz, 2H), 7.52 (dd, J = 8.0, 3.9 Hz, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.04 (d, J = 9.1 Hz, 1H), 6.60 (t, J = 
4.3 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 162.48 (s), 158.95 (s), 150.50 (s), 149.22 (s), 148.76 (s), 138.91 
(s), 136.90 (s), 128.58 (s), 128.51 (s), 128.14 (q, J = 31.7 Hz), 127.53 (s), 126.01 (q, J = 3.7 Hz), 125.23 (s), 
125.17 (q, J = 272.1 Hz), 122.68 (s), 118.42 (s), 111.75 (s), 52.59 (s); HRMS (ESI) m/z calcd. for 
C21H15F3N4O [M + H]+: 397.1271, found: 397.1273. 
7-((4-Methylpyrimidin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (34): white solid, yield: 
46% (113 mg), m.p.: 147–149 °C, C22H17F3N4O; 1H-NMR (500 MHz, DMSO) δ 10.12 (s, 1H), 8.86 (dd, J 
= 4.1, 1.5 Hz, 1H), 8.31 (dd, J = 8.3, 1.3 Hz, 1H), 8.16 (d, J = 5.0 Hz, 1H), 8.11 (d, J = 9.4 Hz, 1H), 7.75 (d, 
J = 8.6 Hz, 1H), 7.66 (d, J = 8.3 Hz, 2H), 7.60 (d, J = 8.2 Hz, 2H), 7.55 (dd, J = 8.3, 4.2 Hz, 1H), 7.42 (d, J 
= 8.6 Hz, 1H), 7.09 (d, J = 9.4 Hz, 1H), 6.52 (d, J = 5.0 Hz, 1H), 2.26 (s, 3H); 13C-NMR (126 MHz, DMSO) 
δ 167.94 (s), 162.02 (s), 158.11 (s), 150.04 (s), 148.83 (s), 148.65 (s), 138.53 (s), 136.53 (s), 128.15 (s), 128.10 
(s), 127.67 (q, J = 31.5 Hz), 127.22 (s), 125.61 (q, J = 3.5 Hz), 125.01 (s), 124.81 (q, J = 271.6 Hz), 122.29 
(s), 118.03 (s), 110.84 (s), 52.09 (s), 24.11 (s). 
7-((4-Methylpyrimidin-2-ylamino)(4-nitrophenyl)methyl)quinolin-8-ol (35): white solid, yield: 19% (44 
mg), m.p.: 136–138 °C, C21H17N5O3; 1H-NMR (500 MHz, DMSO) δ 10.15 (s, 1H), 8.84 (d, J = 2.5 Hz, 1H), 
8.28 (d, J = 7.9 Hz, 1H), 8.18–8.09 (m, 4H), 7.71 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 8.4 Hz, 2H), 7.53 (dd, J = 
8.1, 4.0 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 9.2 Hz, 1H), 6.51 (d, J = 4.8 Hz, 1H), 2.24 (s, 3 H); 
13C-NMR (126 MHz, CDCl3) δ 168.00 (s), 161.51 (s), 158.09 (s), 151.33 (s), 149.69 (s), 148.45 (s), 146.26 
(s), 138.10 (s), 136.10 (s), 128.10 (s), 127.75 (s), 126.73 (s), 124.09 (s), 123.53 (s), 121.94 (s), 117.68 (s), 
110.53 (s), 51.69 (s), 23.69 (s); HRMS (ESI) m/z calcd. for C21H17N5O3 [M + H]+: 388.1404, found: 
388.1409. 
7-((4-Methylpyrimidin-2-ylamino)(4-(pentafluorothio)phenyl)methyl)quinolin-8-ol (36): white solid, yield: 
68% (191 mg), m.p.: 164–165 °C, C21H17F5N4OS; 1H-NMR (500 MHz, DMSO) δ 10.16 (s, 1H), 8.87 (dd, 
J = 4.1, 1.5 Hz, 1H), 8.31 (dd, J = 8.3, 1.5 Hz, 1H), 8.17 (d, J = 5.0 Hz, 1H), 8.12 (d, J = 9.4 Hz, 1H), 7.84 
(d, J = 8.9 Hz, 2H), 7.75 (d, J = 8.6 Hz, 1H), 7.59 (d, J = 8.5 Hz, 2H), 7.55 (dt, J = 12.4, 6.2 Hz, 1H), 7.43 
(d, J = 8.6 Hz, 1H), 7.07 (d, J = 9.4 Hz, 1H), 6.52 (t, J = 6.2 Hz, 1H), 2.26 (s, 3H); 13C-NMR (126 MHz, 
DMSO) δ 168.2–167.74 (m), 161.98 (s), 158.28–157.83 (m), 152.05–151.32 (m), 150.08 (s), 148.86 (s), 
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148.60 (s), 138.53 (s), 136.54 (s), 128.25(s), 128.16 (s), 127.13 (s), 126.36–126.19 (m), 124.73 (s), 122.34 (s), 
118.09 (s), 110.92 (s), 51.90 (s), 24.11 (s); HRMS (ESI) m/z calcd. for C21H17F5N4OS [M + H]+: 469.1116, 
found: 469.1118. 
7-((4-Fluorophenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (37): white solid, yield: 16% (35 
mg), m.p.: 156–158 °C, C21H17FN4O; 1H-NMR (500 MHz, DMSO) δ 9.97 (s, 1H), 8.82 (d, J = 2.8 Hz, 1H), 
8.27 (d, J = 8.2 Hz, 1H), 8.12 (d, J = 4.9 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.74 (d, J = 8.5 Hz, 1H), 7.51 (dd, 
J = 8.2, 4.1 Hz, 1H), 7.42–7.31 (m, 3H), 7.12–7.03 (m, 2H), 6.98 (t, J = 12.1 Hz, 1H), 6.47 (d, J = 4.9 Hz, 
1H), 2.22 (s,  H); 13C-NMR (126 MHz, CDCl3) δ 167.90 (s), 161.58 (s), 158.06 (s), 160.95 (d, J = 242.0 
Hz), 149.37 (s), 148.30 (s), 139.53 (s), 138.07 (s), 136.05 (s), 128.87 (d, J = 8.1 Hz), 127.51 (s), 126.74 (s), 
125.34 (s), 121.71 (s), 117.43 (s), 114.85 (d, J = 21.2 Hz), 110.20 (s), 51.25 (s), 23.63 (s); HRMS (ESI) m/z 
calcd. for C21H17FN4O [M + H]+: 361.1459, found: 361.1460. 
7-((4-Iodophenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (38): white solid, yield: 18% (51 mg), 
m.p.: 139–142 °C, C21H17IN4O; 1H-NMR (500 MHz, DMSO) δ 9.99 (s, 1 H), 8.82 (s, 1 H), 8.27 (d, J = 8.2 
Hz, 1 H), 8.12 (d, J = 4.3 Hz, 1 H), 7.96 (d, J = 9.3 Hz, 1 H), 7.70 (d, J = 8.4 Hz, 1 H), 7.61 (d, J = 7.8 Hz, 2 
H), 7.52 (dd, J = 7.8, 3.8 Hz, 1 H), 7.37 (d, J = 8.4 Hz, 1 H), 7.15 (d, J = 7.6 Hz, 2 H), 6.91 (d, J = 9.3 Hz, 1 
H), 6.48 (d, J = 4.5 Hz, 1 H), 2.22 (s, 3 H) 13C-NMR (126 MHz, DMSO) δ 167.89 (s), 162.01 (s), 158.01 (s), 
149.90 (s), 148.77 (s), 143.75 (s), 138.51 (s), 137.34 (s), 136.50 (s), 129.86 (s), 128.00 (s), 127.23 (s), 125.35 
(s), 122.20 (s), 117.91 (s), 110.69 (s), 92.81 (s), 51.91 (s), 24.06 (s); HRMS (ESI) m/z calcd. for C21H17IN4O 
[M + H]+: 469.0520, found: 469.0525. 
7-((4-Bromophenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (39): ivory-white solid, yield: 29% 
(73 mg), m.p.: 143–145 °C, C21H17BrN4O; 1H-NMR (500 MHz, DMSO) δ 10.00 (s, 1H), 8.82 (s, 1H), 8.27 
(d, J = 7.9 Hz, 1H), 8.12 (d, J = 4.5 Hz, 1H), 7.98 (d, J = 9.2 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 
7.8, 3.8 Hz, 1H), 7.44 (d, J = 8.1 Hz, 2H), 7.38 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 9.3 
Hz, 1H), 6.48 (d, J = 4.6 Hz, 1H), 2.22 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.85 (s), 161.57 (s), 149.46 
(s), 148.34 (s), 142.86 (s), 138.07 (s), 136.06 (s), 131.04 (s), 129.24 (s), 127.57 (s), 126.77 (s), 124.91 (s), 
121.77 (s), 119.59 (s), 117.48 (s), 110.27 (s), 51.39 (s), 24.39 (s); HRMS (ESI) m/z calcd. for C21H17BrN4O 
[M + H]+: 421.0659, found: 421.0664. 
7-((4-Chlorophenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (40): white solid, yield: 40% (90 
mg), m.p.: 139–141 °C, C21H17ClN4O; 1H-NMR (500 MHz, DMSO) δ 10.04 (s, 1H), 8.86 (dd, J = 3.9, 1.3 
Hz, 1H), 8.30 (d, J = 8.3 Hz, 1H), 8.15 (d, J = 4.9 Hz, 1H), 8.02 (d, J = 9.4 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 
7.55 (dd, J = 8.2, 4.1 Hz, 1H), 7.44–7.37 (m, 3H), 7.34 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 9.4 Hz, 1H), 6.51 (d, 
J = 5.0 Hz, 1H), 2.25 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 167.90 (s), 162.01 (s), 158.05 (s), 149.90 (s), 
148.78 (s), 142.86 (s), 138.51 (s), 136.51 (s), 131.53 (s), 129.29 (s), 128.57 (s), 128.00 (s), 127.19 (s), 125.43 
(s), 122.21 (s), 117.92 (s), 110.70 (s), 51.74 (s), 24.09 (s); HRMS (ESI) m/z calcd. for C21H17ClN4O [M + 
H]+: 377.1164, found: 377.1167. 
7-((4-Methylpyrimidin-2-ylamino)(3-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (41): white solid, yield: 
31% (76 mg), m.p.: 160–163 °C, C22H17F3N4O; 1H-NMR (500 MHz, DMSO) δ 10.08 (s, 1H), 8.91–8.73 
(m, 1H), 8.27 (d, J = 8.2 Hz, 1H), 8.21–8.06 (m, 2H), 7.81–7.70 (m, 2H), 7.67 (d, J = 7.0 Hz, 1H), 7.59–7.44 
(m, 3H), 7.40 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 9.4 Hz, 1H), 6.49 (d, J= 4.7 Hz, 1H), 2.23 (s, 3H); 13C-NMR 
(126 MHz, DMSO) δ 168.00 (s), 161.96 (s), 149.96 (s), 148.87 (s), 145.32 (s), 138.50 (s), 136.54 (s), 131.70 
(s), 129.79 (s), 129.36 (q, J = 31.4 Hz), 128.07 (s), 126.93 (s), 125.18 (s), 124.74 (q, J = 272.43 Hz), 123.87 
(q, J = 3.6 Hz), 123.68 (q, J = 3.7 Hz), 122.30 (s), 118.09 (s), 110.85 (s), 51.95 (s), 24.16 (s); HRMS (ESI) 
m/z calcd. for C22H17F3N4O [M + H]+: 411.1427, found: 411.1428. 
7-((3,5-bis(Trifluoromethyl)phenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (42): white solid, 
yield: 59% (169 mg), m.p.: 128–130 °C, C23H16F6N4O; 1H-NMR (500 MHz, DMSO) δ 10.24 (s, 1H), 8.84 
(d, J = 2.8 Hz, 1H), 8.36–8.23 (m, 2H), 8.15 (d, J = 4.8 Hz, 1H), 8.08 (s, 2H), 7.93 (s, 1H), 7.77 (d, J = 8.5 
Hz, 1H), 7.53 (dd, J = 8.2, 4.1 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 9.4 Hz, 1H), 6.52 (d, J = 4.9 
Hz, 1H), 2.24 (s, 3H); 13C-NMR (126 MHz, CDCl3) δ 167.63 (s), 161.38 (s), 157.64 (s), 149.65 (s), 148.57 
(s), 146.83 (s), 138.06 (s), 136.14 (s), 130.19 (q, J = 32.9 Hz), 127.80 (s), 127.63 (s), 125.96 (s), 123.97 (s), 
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123.35 (q, J = 272.8 Hz), 122.02 (s), 120.80–120.55 (m), 117.93 (s), 110.72 (s), 51.60 (s), 23.62 (s); HRMS 
(ESI) m/z calcd. for C23H16F6N4O [M + H]+: 479.1301, found: 479.1304. 
7-((2,4-bis(Trifluoromethyl)phenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (43): white solid, 
yield: 16% (46 mg), m.p.: 199–201 °C, C23H16F6N4O; 1H-NMR (500 MHz, DMSO) δ 9.97 (s, 1H), 8.81 (d, 
J = 2.4 Hz, 1H), 8.28 (d, J = 7.8 Hz, 1H), 8.08 (s, 1H), 8.03 (d, J = 6.0 Hz, 1H), 7.99–7.95 (m, 2H), 7.80 (bs, 
1H), 7.52 (dd, J = 8.1, 3.9 Hz, 1H), 7.33 (dd, J = 11.7, 9.2 Hz, 2H), 7.21 (d, J = 4.7 Hz, 1H), 6.47 (d, J = 4.7 
Hz, 1H), 2.19 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 169.04 (s), 161.45 (s), 158.49 (s), 150.79 (s), 148.79 
(s), 138.45 (s), 136.53 (s), 131.63 (s), 129.90–129.72 (m), 128.66 (q, J = 31.4 Hz), 128.55 (q, J = 32.7 Hz), 
128.26 (s), 127.05–126.81 (m), 124.01 (q, J = 275.4 Hz), 123.97 (q, J = 272.2 Hz), 123.57–123.27 (m), 122.34 
(s), 117.30 (s), 116.90 (s), 110.80 (s), 49.76 (s), 24.05 (s); HRMS (ESI) m/z calcd. for C23H16F6N4O [M + 
H]+: 479.1301, found: 479.1307. 
7-((4-Fluoro-3-(trifluoromethyl)phenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (44): white 
solid, yield: 25% (64 mg), m.p.: 89–92 °C, C22H16F4N4O; 1H-NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 
8.82 (bs, 1H), 8.26 (d, J = 5.6 Hz, 1H), 8.19–8.08 (m, 2H), 7.83–7.64 (m, 3H), 7.51 (dd, J = 5.6, 3.6 Hz, 1 
H), 7.43–7.31 (m, 2H), 7.01 (d, J = 7.7 Hz, 1H), 6.49 (bs, 1H), 2.22 (s, 3H); 13C-NMR (126 MHz, CDCl3) 
δ 167.49 (bs), 161.44 (s), 157.95–157.18 (m), 157.63 (d, J = 252.6 Hz), 149.50 (s), 148.44 (s), 140.49 (s), 
138.05 (s), 136.09 (s), 133.81 (d, J = 8.5 Hz), 127.67 (s), 126.23 (s), 125.27 (d, J = 3.4 Hz), 124.56 (s), 123.77 
(s), 121.87 (s), 117.70 (s), 117.08 (d, J = 20.5 Hz), 110.49 (s), 51.15 (s), 23.62 (s); HRMS (ESI) m/z calcd. 
for C22H16F4N4O [M + H]+: 429.1333, found: 429.1337. 
7-((3-Fluoro-5-(trifluoromethyl)phenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (45): ivory-
white solid, yield: 15% (39 mg), m.p.: decomposed 92 °C, C22H16F4N4O; 1H-NMR (500 MHz, DMSO) δ 
10.22 (s, 1H), 8.87 (d, J = 3.0 Hz, 1H), 8.31 (d, J = 8.1 Hz, 1H), 8.21 (d, J = 9.5 Hz, 1H), 8.18 (d, J = 4.8 Hz, 
1H), 7.77 (d, J = 8.5 Hz, 1H), 7.65 (s, 1H), 7.58–7.52 (m, 3H), 7.44 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 9.4 Hz, 
1H), 6.55 (d, J = 4.9 Hz, 1H), 2.27 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 162.39 (d, J = 246.5 Hz), 161.86 
(s), 150.03 (s), 148.97 (s), 148.74 (d, J = 6.8 Hz), 138.51 (s), 136.57 (s), 131.72–131.06 (m), 128.19 (s), 126.64 
(s), 124.61 (s), 123.80 (dq, J = 272.7, 4.2 Hz), 122.42 (s), 120.28–119.83 (m), 118.40 (d, J = 22.0 Hz), 118.26 
(s), 111.74–111.36 (m), 111.08 (s), 51.86 (s), 24.10 (s); HRMS (ESI) m/z calcd. for C22H16F4N4O [M + H]+: 
429.1333, found: 429.1336. 
7-((5-Bromopyrimidin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (46): white solid, yield: 
15% (43 mg), m.p.: 146–148 °C, C21H14BrF3N4O; 1H-NMR (500 MHz, DMSO) δ 10.12 (s, 1H), 8.84 (d, J 
= 2.2 Hz, 1H), 8.50 (d, J = 8.9 Hz, 1H), 8.41 (s, 2H), 8.28 (d, J = 7.9 Hz, 1H), 7.70–7.61 (m, 3H), 7.59–7.49 
(m, 3H), 7.39 (d, J = 8.4 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H); 13C-NMR (126 MHz, CDCl3) δ 160.07 (s), 149.81 
(s), 148.45 (s), 147.38 (s), 138.07 (s), 136.11 (s), 127.82 (s), 127.75 (s), 127.19 (q, J = 31.8 Hz), 126.52 (s), 
125.26 (q, J = 4.0 Hz), 124.77 (q, J = 272.0 Hz), 123.91 (s), 121.93 (s), 117.62 (s), 106.09 (s), 52.12 (s); HRMS 
(ESI) m/z calcd. for C21H14BrF3N4O [M + H]+: 475.0376, found: 475.0384. 
7-((2-Hydroxyphenyl)(4-methylpyrimidin-2-ylamino)methyl)quinolin-8-ol (47): caesious solid, yield: 15% 
(32 mg), m.p.: decomposed 179 °C, C21H18N4O2; 1H-NMR (500 MHz, DMSO) δ 9.81 (s, 1 H), 9.49 (s, 1 
H), 8.82 (d, J = 2.9 Hz, 1 H), 8.28 (d, J = 7.7 Hz, 1 H), 8.11 (d, J = 4.9 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 
7.51 (dd, J = 8.3, 4.2 Hz, 1H), 7.49 (d, J = 9.2 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.24 (d, J = 7.2 Hz, 1H), 
7.04 (t, J = 7.1 Hz, 1H), 6.99 (d, J = 9.0 Hz, 1H), 6.77 (d, J = 7.9 Hz, 1H), 6.72 (t, J = 7.4 Hz, 1H), 6.46 (d, J 
= 4.9 Hz, 1H), 2.23 (s, 3H); 13C-NMR (126 MHz, DMSO) δ 167.64 (s), 161.85 (s), 157.94 (s), 155.36 (s), 
150.18 (s), 148.47 (s), 138.47(s), 136.39 (s), 129.22 (s), 128.76 (s), 128.12 (s), 127.85 (s), 127.80 (s), 125.59 
(s), 121.89 (s), 119.01 (s), 116.93 (s), 115.63 (s), 110.29 (s), 48.89 (s), 24.13 (s); HRMS (ESI) m/z calcd. for 
C21H18N4O2 [M + H]+: 359.1503, found: 359.1509. 
2-Methyl-7-((4-methylpyrimidin-2-ylamino)(4-(trifluoromethyl)phenyl)methyl)quinolin-8-ol (48): white 
solid, yield: 25% (64 mg), m.p.: 123–125 °C, C23H19F3N4O; 1H-NMR (500 MHz, DMSO) δ 9.59 (s, 1H), 
8.19–8.15 (m, 2H), 8.09 (d, J = 9.4 Hz, 1H), 7.69–7.64 (m, 3H), 7.59 (d, J = 8.3 Hz, 2H), 7.42 (d, J = 8.4 Hz, 
1H), 7.36 (d, J = 8.6 Hz, 1H), 7.07 (d, J = 9.4 Hz, 1H), 6.52 (d, J = 5.0 Hz, 1H), 2.70 (s, 3H), 2.26 (s, 3H); 
13C-NMR (126 MHz, DMSO) δ 167.96 (s), 162.04 (s), 158.23 (s), 157.51 (s), 149.14 (s), 148.73 (s), 137.80 
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(s), 136.56 (s), 128.09 (s), 127.52 (q, J = 31.6 Hz), 126.17 (s), 126.09 (s), 125.57 (q, J = 3.5 Hz), 124.81 (q, J 
= 271.9 Hz), 124.77 (s), 123.09 (s), 117.87 (s), 110.83 (s), 52.08 (s), 25.14 (s), 24.12 (s); HRMS (ESI) m/z 
calcd. for C23H19F3N4O [M + H]+: 425.1584, found: 425.1585. 
3.2. Cell Culture 
U251 MG cell line was a gift from Szabolcs Bellyei, the University of Pecs (originally obtained 
from American Type Culture Collection, Manassas, VA, USA). Cells were grown at 37 °C under 5% 
CO2 and 100% humidity in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% 
fetal calf serum (FCS) (Sigma-Aldrich, Budapest, Hungary), and penicillin-streptomycin antibiotics. 
3.3. End Point Cytoprotection Assay 
For cytoprotection assays, 104 cells were seeded into each well of 96-well cell culture plates 
(Costar, Corning Inc., Corning, NY, USA) in culture medium containing 10% FCS. The following day, 
cells were treated with an increasing concentration of test compounds in the presence of 250 µM H2O2 
(Sigma-Aldrich, Budapest, Hungary). The H2O2 concentration to elicit cell injury was predetermined 
in a pilot experiment (data not shown) and was set to induce a decrease in viability of 65–75% after 
24 h Plate-to-plate variation was monitored using a dilution series of a known cytoprotective 
compound that was tested on each plate. Cell viability was recorded 24 h after treatment. Resazurin 
reagent (Sigma-Aldrich) was dissolved in phosphate buffered saline (PBS, pH 7.4) at 0.15 mg/mL 
concentration, sterile filtered (0.22 µm, Merck Millipore, Budapest, Hungary), aliquoted and stored 
at −20 °C. Samples were treated with a final concentration of 25 µg/mL resazurin. After 2 h of 
incubation at 37 °C 5% CO2, fluorescence (530 nm excitation/580 nm emission) was recorded on a 
multimode microplate reader (Cytofluor4000, PerSeptive Biosystems, Foster City, CA, USA). 
Viability was calculated in relation to untreated control cells and blank wells containing media 
without cells. The presented IC50 values (half maximal inhibitory concentration) were determined 
based on dose-response curves plotted in GraphPad Prism® 5. 
3.4. Real-Time Cell Electronic Sensing (RT-CES) Cytoprotection Assay 
A RT cytoprotection assay was performed as previously described [42,48]. Briefly, RT-CES 96-
well E-plate (Roche, Hungary) was coated with gelatin solution (0.2% in PBS) for 20 min at 37 °C, 
then gelatin was washed twice with PBS solution. Growth media (50 µL) was then gently dispensed 
into each well of the 96-well E-plate for background readings by the RT-CES system prior to addition 
of 50 µL of the cell suspension containing 104 U251 MG cells. Plates were kept at room temperature 
in a tissue culture hood for 30 min prior to insertion into the RT-CES device in the incubator to allow 
cells to settle. Cell growth was monitored overnight by measurements of electrical impedance every 
15 min. Continuous recording of impedance in cells was reflected by cell index value. Next day, cells 
were co-treated with 250 µM H2O2 and test compounds. Treated and control wells were dynamically 
monitored over 48 h by measurements of electrical impedance every 5 min. The raw plate reads for 
each titration point were normalized relative to the cell index status right before treatment. Each 
treatment was repeated in three wells per plate during the experiments. 
3.5. Detection of Mitochondrial Membrane Potential 
Mitochondrial membrane potential was measured as described previously [49] U251 cells (6 × 
104) were plated in 24-well tissue culture plates (Corning Life Sciences, Corning, NY, USA) in RPMI 
10% FCS and were treated in 500 µL media containing 500 µM H2O2 with or without test compounds. 
Untreated controls cells were supplemented with 500 µL cell culture media. After 2 h, the 
supernatants were harvested. Cells were washed with PBS, trypsinized, pooled with the 
corresponding supernatant, and centrifuged (2000 rpm, 5 min). The pellet was resuspended and 
incubated for 15 min in 5 µg/mL JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolocarbocyanine iodide, Chemodex) containing media in final volume 300 µL 
at 37 °C. Finally, using FL2 (585/42 nm) -FL1 (530/30 nm) channels, the red–green fluorescence 
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intensity of 6 × 103 events was acquired immediately on a FACSCalibur flow cytometer. Data were 
analyzed using CellQuestTM software (CellQuest Pro v5.1, Becton Dickinson, Franklin Lakes, NJ, 
USA) gating out debris. Bar graphs show the percentage of FL1 positive cells visualized by GraphPad 
Prism® 5. For significance analysis, a Student’s t-test was applied in Microsoft Excel. 
3.6. Gene Expression Analysis 
The day before measurement, U-251 MG cells were seeded in 24-well microtiter plates with 
100,000 cells/well density. Cells were treated with either vehicle (solvent control; ≤0.01% DMSO) or 
with 8-HQ analogues: 21, 34, 47, and 48 at two different concentrations: 100 nM or 300 nM. After 6 
hours of incubation the medium was removed, and cells were rinsed with PBS. Cells were collected 
for RNA isolation in RA1 Lysis Buffer (Macherey-Nagel, Germany) supplemented with 1% beta-
mercaptoethanol. Total RNA was purified with the Direct-zol kit (Zymo Research, Irvine, CA, USA) 
according to the manufacturer’s protocol. Total RNA was converted into complementary DNA 
(cDNA) using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA, USA) in 
a volume of 10 µL. 0.75 µL cDNA template was used (19 ng) in each PCR reaction. Quantitative real-
time PCR was performed on the LightCycler 96 instrument (Roche) with gene-specific primers and 
the SYBRGreen protocol. NormFinder software [50] was used to calculate the most suitable 
housekeeping genes (TUBB and PPIA) for relative expression ratio calculation. For significance 
analysis, a Student’s t-test was applied in Microsoft Excel. Table 4 lists the primer sequences used. 
Table 4. Primer sequences for Quantitative real-time PCR (qRT-PCR) analysis. 
Gene Name Abbreviation Forward_Sequence Reverse_Sequence 
Tubulin beta class I TUBB ataccttgaggcgagcaaaa ctgatcacctcccagaacttg 
Peptidylprolyl isomerase A PPIA atgctggacccaacacaaat tctttcactttgccaaacacc 
Heme oxygenase 1 HMOX1 ggcagagggtgatagaagagg agctcctgcaactcctcaaa 
Vascular endothelial growth factor VEGF gcagcttgagttaaacgaacg ggttcccgaaaccctgag 
Solute carrier family 2 member 1 GLUT1 ccccatcccatggttcatc tgaggtccagttggagaagc 
4. Conclusions 
Our synthesized 8HQ analogs were tested for cytoprotective activity in different assays and a 
handful of compounds were selected for further test. As expected, maintenance of mitochondrial 
membrane potential in oxidative stress was a key factor for their activity. Induction of hypoxia related 
genes under the regulation of HIF1A may be a crucial mechanistic step for cytoprotective activity. 
Based on our results, lead compounds will be further tested in animal models of different CNS 
diseases where oxidative stress is involved. 
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Compounds described in the current study are protected by patent #WO2011148208. 
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